185 related articles for article (PubMed ID: 36001857)
1. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.
Deek MP; Van der Eecken K; Sutera P; Deek RA; Fonteyne V; Mendes AA; Decaestecker K; Kiess AP; Lumen N; Phillips R; De Bruycker A; Mishra M; Rana Z; Molitoris J; Lambert B; Delrue L; Wang H; Lowe K; Verbeke S; Van Dorpe J; Bultijnck R; Villeirs G; De Man K; Ameye F; Song DY; DeWeese T; Paller CJ; Feng FY; Wyatt A; Pienta KJ; Diehn M; Bentzen SM; Joniau S; Vanhaverbeke F; De Meerleer G; Antonarakis ES; Lotan TL; Berlin A; Siva S; Ost P; Tran PT
J Clin Oncol; 2022 Oct; 40(29):3377-3382. PubMed ID: 36001857
[No Abstract] [Full Text] [Related]
2. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial.
Tang C; Sherry AD; Haymaker C; Bathala T; Liu S; Fellman B; Cohen L; Aparicio A; Zurita AJ; Reuben A; Marmonti E; Chun SG; Reddy JP; Ghia A; McGuire S; Efstathiou E; Wang J; Wang J; Pilie P; Kovitz C; Du W; Simiele SJ; Kumar R; Borghero Y; Shi Z; Chapin B; Gomez D; Wistuba I; Corn PG
JAMA Oncol; 2023 Jun; 9(6):825-834. PubMed ID: 37022702
[TBL] [Abstract][Full Text] [Related]
3. Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer.
Deek MP; Taparra K; Dao D; Chan L; Phillips R; Gao RW; Kwon ED; Deville C; Song DY; Greco S; Carducci MA; Eisenberger M; DeWeese TL; Denmeade S; Pienta K; Paller CJ; Antonarakis ES; Olivier KR; Park SS; Stish BJ; Tran PT
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):387-395. PubMed ID: 32798608
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?
Slaoui A; Albisinni S; Aoun F; Assenmacher G; Al Hajj Obeid W; Diamand R; Regragui S; Touzani A; Bakar A; Mesfioui A; Karmouni T; Ameur A; Elkhader K; Koutani A; Ibnattya A; Roumeguere T; Peltier A
World J Urol; 2019 Nov; 37(11):2343-2353. PubMed ID: 30706122
[TBL] [Abstract][Full Text] [Related]
5. WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer.
Sutera P; Deek MP; Van der Eecken K; Shetty AC; Chang JH; Hodges T; Song Y; Verbeke S; Van Dorpe J; Fonteyne V; De Laere B; Mishra M; Rana Z; Molitoris J; Ferris M; Ross A; Schaeffer E; Roberts N; Song DY; DeWeese T; Pienta KJ; Antonarakis ES; Ost P; Tran PT
Int J Radiat Oncol Biol Phys; 2023 Apr; 115(5):1095-1101. PubMed ID: 36708787
[TBL] [Abstract][Full Text] [Related]
6. Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer.
Deek MP; Taparra K; Phillips R; Velho PI; Gao RW; Deville C; Song DY; Greco S; Carducci M; Eisenberger M; DeWeese TL; Denmeade S; Pienta K; Paller CJ; Antonarakis ES; Olivier KR; Park SS; Tran PT; Stish BJ
Eur Urol Oncol; 2021 Jun; 4(3):447-455. PubMed ID: 32536574
[TBL] [Abstract][Full Text] [Related]
7. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
Hasan H; Deek MP; Phillips R; Hobbs RF; Malek R; Radwan N; Kiess AP; Dipasquale S; Huang J; Caldwell T; Leitzel J; Wendler D; Wang H; Thompson E; Powell J; Dudley S; Deville C; Greco SC; Song DY; DeWeese TL; Gorin MA; Rowe SP; Denmeade S; Markowski M; Antonarakis ES; Carducci MA; Eisenberger MA; Pomper MG; Pienta KJ; Paller CJ; Tran PT
BMC Cancer; 2020 Jun; 20(1):492. PubMed ID: 32487038
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: Analysis of STOMP and ORIOLE trials.
Cao S; Hu X; Shao Y; Li X
Asian J Surg; 2023 May; 46(5):2202. PubMed ID: 36526472
[No Abstract] [Full Text] [Related]
9. Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapy.
Wenzel M; Garcia CC; Hoeh B; Jorias C; Humke C; Koll F; Tselis N; Rödel C; Graefen M; Tilki D; Chun FKH; Mandel P
Prostate; 2023 Oct; 83(14):1365-1372. PubMed ID: 37464963
[TBL] [Abstract][Full Text] [Related]
10. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
Privé BM; Janssen MJR; van Oort IM; Muselaers CHJ; Jonker MA; de Groot M; Mehra N; Verzijlbergen JF; Scheenen TWJ; Zámecnik P; Barentsz JO; Gotthardt M; Noordzij W; Vogel WV; Bergman AM; van der Poel HG; Vis AN; Oprea-Lager DE; Gerritsen WR; Witjes JA; Nagarajah J
BMC Cancer; 2020 Sep; 20(1):884. PubMed ID: 32928177
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes of metastasis-directed treatment using
Hurmuz P; Onal C; Ozyigit G; Igdem S; Atalar B; Sayan H; Akgun Z; Kurt M; Ozkok HB; Selek U; Oymak E; Tilki B; Guler OC; Mustafayev TZ; Saricanbaz I; Rzazade R; Akyol F
Strahlenther Onkol; 2020 Nov; 196(11):1034-1043. PubMed ID: 32617620
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer.
Rogowski P; Trapp C; von Bestenbostel R; Schmidt-Hegemann NS; Shi R; Ilhan H; Kretschmer A; Stief C; Ganswindt U; Belka C; Li M
Radiat Oncol; 2021 Jun; 16(1):125. PubMed ID: 34193194
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of imaging-guided metastasis-directed therapy for oligorecurrent prostate cancer: revolution or devolution?
Albisinni S; Van Damme J; Aoun F; Bou Kheir G; Roumeguère T; De Nunzio C
Minerva Urol Nefrol; 2020 Jun; 72(3):279-291. PubMed ID: 32083417
[TBL] [Abstract][Full Text] [Related]
14. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
Ost P; Reynders D; Decaestecker K; Fonteyne V; Lumen N; De Bruycker A; Lambert B; Delrue L; Bultijnck R; Claeys T; Goetghebeur E; Villeirs G; De Man K; Ameye F; Billiet I; Joniau S; Vanhaverbeke F; De Meerleer G
J Clin Oncol; 2018 Feb; 36(5):446-453. PubMed ID: 29240541
[TBL] [Abstract][Full Text] [Related]
15. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
Armstrong AJ; Azad AA; Iguchi T; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Alcaraz A; Alekseev B; Shore ND; Gomez-Veiga F; Rosbrook B; Zohren F; Yamada S; Haas GP; Stenzl A
J Clin Oncol; 2022 May; 40(15):1616-1622. PubMed ID: 35420921
[No Abstract] [Full Text] [Related]
16. Oligometastatic Prostate Cancer Treated with Metastasis-Directed Therapy Guided by Positron Emission Tomography: Does the Tracer Matter?
Lanfranchi F; Belgioia L; Marcenaro M; Zanardi E; Timon G; Riondato M; Giasotto V; Zawaideh JP; Tomasello L; Mantica G; Piol N; Borghesi M; Traverso P; Satragno C; Panarello D; Scaffidi C; Romagnoli A; Rebuzzi SE; Coco A; Spina B; Morbelli S; Sambuceti G; Terrone C; Barra S; Fornarini G; Bauckneht M
Cancers (Basel); 2023 Jan; 15(1):. PubMed ID: 36612319
[TBL] [Abstract][Full Text] [Related]
17. Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer.
Glicksman RM; Ramotar M; Metser U; Chung PW; Liu Z; Vines D; Finelli A; Hamilton R; Fleshner NE; Perlis N; Zlotta AR; Bayley A; Helou J; Raman S; Kulkarni G; Catton C; Lam T; Chan R; Warde P; Gospodarowicz M; Jaffray DA; Berlin A
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):693-704. PubMed ID: 36031465
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
Phillips R; Shi WY; Deek M; Radwan N; Lim SJ; Antonarakis ES; Rowe SP; Ross AE; Gorin MA; Deville C; Greco SC; Wang H; Denmeade SR; Paller CJ; Dipasquale S; DeWeese TL; Song DY; Wang H; Carducci MA; Pienta KJ; Pomper MG; Dicker AP; Eisenberger MA; Alizadeh AA; Diehn M; Tran PT
JAMA Oncol; 2020 May; 6(5):650-659. PubMed ID: 32215577
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
